<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04501211</url>
  </required_header>
  <id_info>
    <org_study_id>1706966663</org_study_id>
    <nct_id>NCT04501211</nct_id>
  </id_info>
  <brief_title>Open Label Transdermal Granisetron to Relieve Chronic Nausea and Emesis</brief_title>
  <official_title>Open Label Transdermal Granisetron to Relieve Chronic Nausea and Emesis and to Reduce Medical Utilization in Patients With Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kyowa Kirin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy of open -label transdermal patch on chronic nausea and emesis in&#xD;
      patients with gastroparesis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastroparesis is a chronic syndrome associated with a delay in stomach emptying. The clinical&#xD;
      presentation of gastroparesis is very heterogeneous but can generally categorized into&#xD;
      emesis-predominant, regurgitation-predominant and dyspeptic-predominant gastroparesis.&#xD;
&#xD;
      The underlying cause of nausea is very difficult to identify, and physician is often treat&#xD;
      nausea symptomatically with anti-nausea and anti-emetic medications.4, 5 Phenothiazine's such&#xD;
      as prochlorperazine (Compazine®), promethazine (Phenergan®), and trimethobenzamide (Tigan®)&#xD;
      have significant side effects and the potential of withdraw symptoms when these medications&#xD;
      are stopped. Serotonin (5- HT3) antagonists have central emetic effects and have been&#xD;
      utilized in acute chemotherapy-induced nausea and vomiting. Ondansetron, granisetron,&#xD;
      palonosetron, and dolasetron are currently available as 5- HT3 antagonists for nausea and&#xD;
      emesis. Oral dissolving and oral tablet formulation is suboptimal in outpatients with&#xD;
      frequent emesis. Transdermal formulation may be optimal for patients with prolong nausea and&#xD;
      vomiting, but data for chronic symptoms associated with gastroparesis is very limited.&#xD;
&#xD;
      An open-label, uncontrolled treatment pilot study with 2-week cycles of granisetron&#xD;
      transdermal patch for 24 weeks in patients with chronic nausea and vomiting associated with&#xD;
      gastroparesis&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Abandoned due to limited resources&#xD;
  </why_stopped>
  <start_date type="Anticipated">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with improvement in chronic nausea and emesis.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Incidence of participants who benefitted from the use of the patch at the end of 2 weeks, 8 weeks, 16 weeks and 24 weeks as assessed by the Gastroparesis Cardinal Symptom Index Nausea-Vomiting (GCSI-N/V). Mean subscale scores will compared for improvement every 6 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with reduced medical utilization for gastroparesis.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Incidence of participants who required less medical resources during treatment by comparing subject self-reports of medication usage, ER visits, home health therapy, and hospitalizations 12 weeks before, 12 weeks after, and 24 weeks after treatment with open label transdermal granisetron.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Gastroparesis</condition>
  <arm_group>
    <arm_group_label>Patch arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Transdermal Granisetron patch to be given for application for 24 weeks with 2 weeks on and one week off pattern for a total of 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granisetron</intervention_name>
    <description>transdermal sancuso patch</description>
    <arm_group_label>Patch arm</arm_group_label>
    <other_name>sancuso patch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Documented delayed gastric emptying by 4-hr gastric scintigraphy using the standard&#xD;
             protocol within 12 months.6&#xD;
&#xD;
          2. Symptoms of gastroparesis for &gt;3 months&#xD;
&#xD;
          3. No upper gastrointestinal obstruction by upper endoscopy, barium radiograph, or CT&#xD;
             scan.&#xD;
&#xD;
          4. Gastroparesis Cardinal Symptom Index Nausea-Vomiting (GCSI-N/V) subscale score of &gt;2.0&#xD;
             during a 2-week run-in period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Baseline ECG with QTc &gt;450ms in men or &gt;470ms in women 2. Prolong QT syndrome 3.&#xD;
             History of Torsade's de pointes, ventricular tachycardia, cardiomyopathy or implanted&#xD;
             cardiac defibrillator 4. Use of cardiovascular antiarrhythmic medications 5. Strong&#xD;
             CYP1A1 and CYP3A4 inhibitors that will inhibit metabolism of 5-HT3 antagonists&#xD;
&#xD;
               1. CYP1A1 Inhibitors: pifithrin, ethinyl estradiol, fluvoxamine (Luvox®),&#xD;
                  mexiletine, miconazole, oltipraz , perazine, rofecoxib, aminobenzotriazole,&#xD;
                  isoniazid, lidocaine, zileuton (Zyflo®)&#xD;
&#xD;
               2. CYP3A strong inhibitors: boceprevir, cobicistat (Tybost®), conivaptan&#xD;
                  (Vaprisol®), danoprevir and ritonavir, elvitegravir and ritonavir, grapefruit&#xD;
                  juice, indinavir and ritonavir, itraconazole (Onmel®, Sporanox®), ketoconazole,&#xD;
                  lopinavir and ritonavir (Kaletra®), paritaprevir and ritonavir and (ombitasvir&#xD;
                  and/or dasabuvir), posaconazole (Noxafil®), ritonavir (Norvir®), saquinavir and&#xD;
                  ritonavir), tipranavir and ritonavir, troleandomycin, voriconazole (Vfend®),&#xD;
                  clarithromycin (Biaxin®), diltiazem (Cardizem®, Cartia®, Dilacor®, Dilt-CD®,&#xD;
                  Diltia XT®, Taztia XT®, Tiazac®), idelalisib (Zydelig®), nefazodone (Serzone®),&#xD;
                  nelfinavir (Viracept®) 6. Serotonergic drugs that may increase the risk of&#xD;
                  serotonin syndrome&#xD;
&#xD;
               1. Selective serotonin reuptake inhibitors (SSRIs)&#xD;
&#xD;
               2. Selective norepinephrine reuptake inhibitors (SNRIs)&#xD;
&#xD;
               3. Others: monoamine oxidase inhibitors: selegiline (Emsam®), isocarboxazid&#xD;
                  (Marplan®), pheneizine (Nardil®), tranylcypromine (Parnate®), mirtazapine&#xD;
                  (Remeron®), fentanyl (Sublimaze®), lithium (Eskalith®, Lithobid®), tramadol&#xD;
                  (ConZip®, Rybix®, Ryzolt®, Ultram®), intravenous methylene blue 7. Any comorbid&#xD;
                  condition that may prohibit enrollment 8. Other causes of nausea identified by&#xD;
                  the investigators other than gastroparesis 9. Any contraindications for 5HT3&#xD;
                  receptor antagonists 10. Non-ambulatory patients: bed-ridden, nursing home&#xD;
                  resident, etc. 11. Pregnancy 12. Unable to give own informed consent 13.&#xD;
                  Prisoners&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John M Wo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 31, 2018</study_first_submitted>
  <study_first_submitted_qc>August 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2020</study_first_posted>
  <last_update_submitted>August 1, 2020</last_update_submitted>
  <last_update_submitted_qc>August 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>John M. Wo</investigator_full_name>
    <investigator_title>Professor of Gastroenterology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Granisetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

